Neonc Technologies Holdings, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $78.1M
- Price
- $2.71
- % Change (Daily % change from the live per-ticker quote feed.)
- -9.36%
- Volume
- 228.7K
About
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. It develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company was founded in 2008 and is headquartered in Calabasas, CA.
Quick stats
Shares outstanding28.8M
Computed float10.5M
Float / shares36.5%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001979414
Websitehttps://www.neonctech.com
AI Summary
AI-generated1/50
minorbullishclinical trial
NeOnc among Names with 2026 Breakthroughs that Offer New Hope in the Fight Against Cancer
A paid 24/7 Market News editorial highlights NeOnc Technologies' Phase 2a study of intranasal NEO100 in recurrent Grade III/IV IDH1-mutant glioma, reporting median overall survival of 26.09 months in 24 patients measured from first post-recurrence treatment dose.
The article stresses the data are an uncontrolled survival signal, not randomized proof, with PFS reaching significance only under RANO 2.0 criteria; NeOnc plans to discuss a registrational pathway with the FDA.
A separate confirmed FDA End-of-Phase 1 meeting for the NEO212 program is set for November 17, 2026.
The release is a compensated promotional communication and recaps previously disclosed data, so it should be treated as low-signal marketing rather than new issuer news.
Red flags
- paid editorial: 24/7 Market News is compensated by NTHI for coverage and market outreach
- Phase 2a data uncontrolled; PFS significance dependent on assessment method (RANO 2.0 vs original protocol)
- small 24-patient cohort; survival measured post-recurrence
- forward-looking statements note going-concern risk